Young-Ah Chung Selected Research

ganitumab

6/2014	Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.
4/2014	IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.
1/2013	Epitope-specific mechanisms of IGF1R inhibition by ganitumab.
6/2011	Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Young-Ah Chung Research Topics

Disease

4	Neoplasms (Cancer) 06/2014 - 06/2011
1	Ovarian Neoplasms (Ovarian Cancer) 06/2014
1	Weight Gain 04/2014
1	Carcinoma (Carcinomatosis) 04/2014
1	Hypersensitivity (Allergy) 01/2013
1	Sarcoma (Soft Tissue Sarcoma) 06/2011
1	Osteosarcoma (Osteogenic Sarcoma) 06/2011

Drug/Important Bio-Agent (IBA)

4	ganitumabIBA 06/2014 - 06/2011
3	Insulin-Like Growth Factor I (IGF-1)IBA 06/2014 - 06/2011
2	Insulin-Like PeptidesIBA 06/2014 - 06/2011
2	Insulin (Novolin)FDA Link 06/2014 - 06/2011
2	Insulin-Like Growth Factor II (Somatomedin A)IBA 06/2014 - 01/2013
1	Paclitaxel (Taxol)FDA LinkGeneric 06/2014
1	Biological ProductsIBA 06/2014
1	Cisplatin (Platino)FDA LinkGeneric 06/2014
1	Carboplatin (JM8)FDA LinkGeneric 06/2014
1	PlatinumIBA 06/2014
1	Fluorouracil (Carac)FDA LinkGeneric 04/2014
1	Glucose (Dextrose)FDA LinkGeneric 04/2014
1	LigandsIBA 01/2013
1	TOR Serine-Threonine KinasesIBA 06/2011
1	Glycogen Synthase (Synthase I)IBA 06/2011
1	Mechanistic Target of Rapamycin Complex 1IBA 06/2011
1	Insulin ReceptorIBA 06/2011
1	Sirolimus (Rapamycin)FDA Link 06/2011
1	Monoclonal AntibodiesIBA 06/2011

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 06/2014